Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331487 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia
A Phase 3 study of Diabetes Mellitus, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 719
- Enrollment target
- 20
- Study locations
NCT00331487: Completed Phase 3 study of Diabetes Mellitus, sponsored by Takeda.
NCT00331487 is a Phase 3 study of Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 719 participants, below the 1,864-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00331487, a Phase 3 study of Diabetes Mellitus, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 719 participants
- Enrollment target
- 20
- Study locations
Study Summary
Efficacy comparison of Pioglitazone, once daily (QD), to Rosiglitazone in participants with Type 2 Diabetes
Conditions Studied
Interventions
- DRUG Rosiglitazone
- DRUG Pioglitazone
Study Locations (20)
California
- - Concord
- - Fremont
- - Los Angeles
- - Palos Verdes Estates
- - San Diego
- - Santa Barbara
- - Santa Rosa
Florida
- - Longwood
- - Miami
- - Miami
Alabama
- - Anniston
- - Birmingham
Colorado
- - Aurora
- - Englewood
Connecticut
- - Avon
- - Hamden
Georgia
- - Atlanta
- - Fayetteville
Arizona
- - Tucson
Hawaii
- - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 719 participants |
| Start Date | 2000-09 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
What the finished NCT00331487 record still lists
NCT00331487 is an interventional study that assigns participants to a tested intervention. The registered 719 participants enrollment target is mid-sized for trials with a published cap, below the 1,864-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Rosiglitazone is the first listed.
NCT00331487 names 20 study sites across 8 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT00331487 about?
NCT00331487 is a clinical study titled "Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia". Efficacy comparison of Pioglitazone, once daily (QD), to Rosiglitazone in participants with Type 2 Diabetes
What is the current status of trial NCT00331487?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 719 participants. The study started on 2000-09. Estimated completion is 2004-03.
What conditions does trial NCT00331487 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT00331487?
The interventions under investigation include: Rosiglitazone (DRUG), Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00331487?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00331487 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00331487's enrollment target sits among peer trials
719 34th of 208 higher than 175 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents
COMPLETED · Phase 3
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
- NCT05047224 · 720 participants · NA
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
- NCT05309395 · 720 participants · Phase 3
Food Prescriptions to Promote Affordable Diets
- NCT05466214 · 720 participants · NA
Systematic Efficacy Replication Study of Conjoint Behavioral Consultation in Elementary Schools
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia